Abera Bioscience (ABERA) Q4 2025 earnings summary

Executive summary

• Achieved significant milestones, transitioning from preclinical to clinical-stage vaccine development, with the first clinical trial for the pneumococcal vaccine candidate planned for 2026.

• Secured strong financing through grants and targeted share issues, ensuring operational funding for at least the next 12 months.

• Expanded team and strengthened partnerships, positioning for increased visibility and industrial collaborations.

Financial highlights

• Net revenue for 2025 was 11,887 KSEK, down from 14,848 KSEK in 2024, mainly from grants.

• Operating loss for 2025 was -10,577 KSEK, compared to -1,121 KSEK in 2024.

• Net loss for 2025 was -10,453 KSEK, compared to -1,100 KSEK in 2024.

• Cash and cash equivalents at year-end were 23,489 KSEK, up from 6,090 KSEK the previous year.

• Equity increased to 19,286 KSEK from 8,656 KSEK year-over-year.

Outlook and guidance

• Funding secured for at least the next 12 months, supporting planned clinical and development activities.

• First clinical trial for the lead pneumococcal vaccine candidate is targeted to start in 2026.

• Continued focus on advancing influenza vaccine candidates and expanding the pipeline.